P16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma

Japanese Journal of Cancer Research

Volumn 87, Issue 2, 1996, Pages 134-140

  Takeshima, Yukio ^a   Nishisaka, Takashi ^a   Kawano, Ryoji ^a   Kishizuchi, Kentaro ^a   Fujii, Satoshi ^a   Kitaguchi, Souichi ^a   Inai, Kouki ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Lung adenocarcinoma; Non smoker; p16 CDKN2; p53; PCR SSCP

Indexed keywords

ASBESTOS; HORMONE; MICROSATELLITE DNA; ONCOPROTEIN; PROTEIN P53; RADON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; ENVIRONMENTAL FACTOR; FEMALE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LUNG ADENOCARCINOMA; PASSIVE SMOKING; POINT MUTATION; PRIORITY JOURNAL; SILENT GENE; TUMOR SUPPRESSOR GENE;

EID: 0029670325     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb03150.x     Document Type: Article

References (50)

1. Stockwell, H. G., Goldman, A. L., Luman, G. H., Noss, C. I., Armstrong, A. W., Pinkham, P. A., Candelora, E. C. and Brusa, M. R. Environmental tobacco smoke and lung cancer risk in nonsmoking women. J. Natl. Cancer Inst., 84, 1417-1422 (1992).
2. Churg, A. and Greene, F. H. "Pathology of Occupational Lung Disease," pp. 279-325 (1988). Igaku-Shoin, New York.
3. Radford, E. P. and St. Clair Renrd, K. G. Lung cancer in Swedish iron miners exposed to low doses of radon daughters. N. Engl. J. Med., 310, 1485-1494 (1984).
4. Taioli, E. and Wynder, E. L. Endocrine factors and adenocarcinoma of the lung in women. J. Natl. Cancer Inst., 86, 869-870 (1994).
5. Wynder, E. L. and Hoffmann, D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res., 54, 5284-5295 (1994).
6. Fujiuchi, S., Akiba, Y., Osanai, S., Yamazaki, Y., Nakano, H., Ohsaki, Y. and Kikuchi, K. A clinical analysis of lung cancer in women. Lung Cancer, 35, 43-48 (1995) (in Japanese).
7. Hollstein, M., Sidransky, D., Vogestein, B. and Harris, C. C. p53 mutations in human cancers. Science, 253, 49-53 (1991).
8. Harris, C. C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science, 262, 1980-1981 (1993).
9. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C. Mutations in the p53 tumor suppressor gene: clue to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
10. Takeshima, Y., Seyama, T., Bennett, W. P., Akiyama, M., Tokuoka, S., Inai, K., Mabuchi, K., Land, C. E. and Harris, C. C. p53 mutations in lung cancers from nonsmoking atomic-bomb survivors. Lancet, 342, 1520-1521 (1993).
11. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., Takahashi, T. and Ueda, R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52, 734-736 (1992).
12. Serrano, M., Hannon, G. J. and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707 (1993).
13. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stuckert, E., Day, R. S., Johnson, B. E. and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
14. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756 (1994).
15. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91, 11045-11049 (1994).
16. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55, 505-509 (1995).
17. Moulton, T., Samara, G., Chung, W.-Y., Yuan, L., Desai, R., Sisti, M., Bruce, J. and Tycho, B. MTS1/p16/ CDKN2 lesions in primary glioblastoma multiforme. Am. J. Pathol., 146, 613-619 (1995).
18. He, J., Allen, J. R., Collins, P., Allalunis-Turner, M. J., Godbout, R., Day, R. S., III and James, C. D. CDK4 amplification is an alternative mechanism of p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54, 5804-5807 (1994).
19. Schmidt, E. E., Ichimura, K., Reifebberger, G. and Collins, V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54, 6321-6324 (1994).
20. Giani, C. and Finocchiaro, G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res., 54, 6338-6339 (1994).
21. Jen, J., Harper, J. W., Binger, S. H., Binger, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W. and Vogelstein, B. Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353-6358 (1994).
22. Walker, D. G., Duan, W., Popovic, E. A., Kaye, A. H., Tomlinson, F. H. and Lavin, M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res., 55, 20-23 (1995).
23. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S. and Nakamura, Y. Frequent somatic mutation of the MTS1/ CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397 (1994).
24. Liu, Q., Yan, Y.-X., McClure, M., Nakagawa, H., Fujimura, F. and Rustgi, A. K. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene, 10, 619-622 (1995).
25. Zhou, X., Tarmin, L., Yin, J., Jiang, H.-Y., Suzuki, H., Rhyu, M.-G., Abraham, J. M. and Meltzer, S. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene, 9, 3737-3741 (1994).
26. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Shutte, M., Syemour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8, 27-32 (1994).
27. Cheng, J. Q., Jhanwar, S. C., Klein, W. M., Bell, D. W., Lee, W. C., Altomare, D. A., Nobori, T., Olopade, O. I., Buckler, A. J. and Testa, J. R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res., 54, 5547-5551 (1994).
28. Zhang, S.-Y., Klein-Szanto, A. J. P., Sauter, E. R., Shafarenko, M., Mitsunaga, S., Nobori, T., Carson, D. A., Ridge, J. A. and Goodrow, T. L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053 (1994).
29. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A. and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8, 15-21 (1994).
30. ink4) in human breast carcinomas. Cancer Res., 54, 5262-5264 (1994).
31. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res., 55, 1436-1440 (1995).
32. Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. and Nakamura, Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun., 202, 1426-1430 (1994).
33. Washimi, O., Nagatake, M., Osada, H., Ueda, R., Koshikawa, T., Seki, T., Takahashi, T. and Takahashi, T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung carcinoma. Cancer Res., 55, 514-517 (1995).
34. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res., 55, 1448-1451 (1995).
35. Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E. and Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-417 (1994).
36. Spruck, C. H., III, Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M.-F., Gonzarez, F., Tsai, Y. C. and Jones, P. A. p16 gene in uncultured tumors. Science, 370, 183-185 (1994).
37. The Japan Lung Cancer Society. "General Rule for Clinical and Pathological Record of Lung Cancer," pp. 88-117 (1987). Kanahara Co., Tokyo.
38. Goelz, S. E., Hamilton, S. R. and Vogelstein, B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem. Biophys. Res. Commun., 130, 118-126 (1985).
39. Takeshima, Y., Inai, K., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Yonehara, S., Hayashi, Y., Fujihara, M., Yamakido, M., Akiyama, M., Tokuoka, S., Land, C. E. and Harris, C. C. p53 mutations in lung cancers from Japanese mustard gas workers. Carcinogenesis, 15, 2075-2079 (1994).
40. Orita, M., Suzuki, Y., Sekiya, T. and Hayashi, K. Rapid and sensitive detection of point mutation and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879 (1989).
41. Jones, M. H. and Nakamura, Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosome Cancer, 5, 89-90 (1992).
42. Cannon-Albright, L. A., Goldgar, D. E., Meye, L. J., Lewis, C. M., Anderson, D. E., Fountain, J. W., Hegi, M. E., Wiseman, R. W., Petty, E. M., Bale, A. E., Olopade, O. I., Diaz, M. O., Kwiatkowski, D. J., Piepkorn, M. W., Zone, J. J. and Skolnick, M. H. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science, 258, 1148-1152 (1992).
43. Weissenbach, J., Gyapay, G., Dib, C., Vignal, A., Morissette, J., Millasseau, P., Vaysseix, G. and Lathrop, M. A second-generation linkage map of the human genome. Nature, 359, 794-801 (1992).
44. Loughran, O., Edington, K. G., Bery, I. J., Clark, L. J. and Parkinson, E. K. Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res., 54, 5045-5049 (1994).
45. Merlo, A., Gabrielson, E., Askin, F. and Sidransky, D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res., 54, 640-642 (1994).
46. van den Berg, F. M., Baas, I. O., Polak, M. M. and Offeraus, J. A. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am. J. Pathol., 142, 381-385 (1993).
47. Westra, W. H., Johan, A. G., Offerhaus, J. A., Goodman, S. N., Slebos, R. J. C., Polak, M., Baas, I. O., Rodenhuis, S. and Hruban, R. H. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinoma is associated with cigarette smoking. Am. J. Surg. Pathol., 17, 213-220 (1993).
48. Dosaka-Akita, H., Shidoh, M., Fujino, M., Kinoshita, I., Akie, K., Katoh, M. and Kawakami, Y. Abnormal p53 expression in human lung cancer is associated with histological subtypes and patient smoking history. Am. J. Clin. Pathol., 102, 660-664 (1994).
49. Bennett, W. P., Hollstein, M. C., He, A., Zhu, S. M., Resau, J., Trump, B. F., Metcalf, R. A., Welsh, J. A., Gannon, J. V., Lane, D. P. and Harris, C. C. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene, 6, 1779-1784 (1991).
50. Hall, R. A., McKee, P. H., Menge, H. P., Dover, R. and Lane, D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8, 203-207 (1993).